Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer 2024-06-06 19:00
Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy 2024-06-05 19:59
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC 2024-06-05 19:00
GC Genome Highlights Promising New Approach for Non-invasive Colorectal Cancer Detection at ASCO 2024 2024-06-05 14:00
Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% 2024-06-05 11:46
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM 2024-06-05 11:31
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO 2024-06-04 20:50
GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings 2024-06-04 13:00
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety 2024-06-04 12:51
Fapon Biopharma Announces a Safer Immunotherapy for Cancers 2024-06-04 09:42
Minghui Pharmaceutical Presents Phase 1/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting 2024-06-03 21:30
Formosa Laboratories Completes the Acquisition of Synchem to Expand North American CDMO Footprint 2024-06-03 13:01
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting. 2024-06-03 10:57
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis 2024-06-03 09:14
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO 2024-06-02 08:25
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting 2024-06-02 07:13
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting 2024-06-02 03:00
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse 2024-06-01 20:00
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting 2024-06-01 20:00
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy 2024-06-01 19:10
1 14 15 16 17 18 165